These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37032119)

  • 1. Comorbidities and the use of comedications among patients with chronic hepatitis C in Korea: A nationwide cross-sectional study.
    Kwon KM; Shim JJ; Kim GA; Kim BO; Han H; Ahn HJ
    Korean J Intern Med; 2023 May; 38(3):338-348. PubMed ID: 37032119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study.
    Chung JW; Choi HY; Ki M; Jang ES; Jeong SH
    Gut Liver; 2021 Mar; 15(2):295-306. PubMed ID: 32616682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis.
    Hsu PY; Wei YJ; Lee JJ; Niu SW; Huang JC; Hsu CT; Jang TY; Yeh ML; Huang CI; Liang PC; Lin YH; Hsieh MY; Hsieh MH; Chen SC; Dai CY; Lin ZY; Chen SC; Huang JF; Chang JM; Hwang SJ; Chuang WL; Huang CF; Chiu YW; Yu ML
    Clin Mol Hepatol; 2021 Jan; 27(1):186-196. PubMed ID: 33317251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan.
    Liu CH; Yu ML; Peng CY; Hsieh TY; Huang YH; Su WW; Cheng PN; Lin CL; Lo CC; Chen CY; Chen JJ; Ma Q; Brooks-Rooney C; Kao JH
    Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1290-1300. PubMed ID: 30362139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications.
    Boff da Costa R; Boff Costa M; Longo L; Miotto DE; Hirata Dellavia G; Trucollo Michalczuk M; Reis Álvares-da-Silva M
    PLoS One; 2021; 16(2):e0245767. PubMed ID: 33577593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic hepatitis C virus infection in Spain.
    Sicras Mainar A; Navarro Artieda R; Hernández I; Morillo R
    Gastroenterol Hepatol; 2019 Oct; 42(8):465-475. PubMed ID: 31451229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study.
    Hui VW; Au CL; Lam ASM; Yip TC; Tse YK; Lai JC; Chan HL; Wong VW; Wong GL
    Hepatol Int; 2022 Dec; 16(6):1318-1329. PubMed ID: 36074319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea.
    Cho Y; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
    Clin Mol Hepatol; 2015 Dec; 21(4):358-64. PubMed ID: 26770924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
    Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited drug-drug interaction of elbasvir/grazoprevir for chronic hepatitis C.
    Liu CJ; Tseng KC; Lo CC; Tseng IH; Cheng PN
    J Formos Med Assoc; 2020 May; 119(5):933-940. PubMed ID: 31594667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end-stage renal disease on maintenance haemodialysis.
    Taneja S; Duseja A; Mehta M; De A; Verma N; Premkumar M; Dhiman RK; Singh V; Singh MP; Ratho RK; Ramachandran R; Kumar V; Kohli HS
    Liver Int; 2021 Apr; 41(4):705-709. PubMed ID: 33025685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study.
    Kondili LA; Gaeta GB; Ieluzzi D; Zignego AL; Monti M; Gori A; Soria A; Raimondo G; Filomia R; Di Leo A; Iannone A; Massari M; Corsini R; Gulminetti R; Gatti Comini A; Toniutto P; Dissegna D; Russo FP; Zanetto A; Rumi MG; Brancaccio G; Danieli E; Brunetto MR; Weimer LE; Quaranta MG; Vella S; Puoti M
    PLoS One; 2017; 12(2):e0172159. PubMed ID: 28245248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs.
    Roncero C; Villegas JL; Martínez-Rebollar M; Buti M
    Expert Rev Clin Pharmacol; 2018 Oct; 11(10):999-1030. PubMed ID: 30199279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals.
    Pisaturo M; Starace M; Minichini C; De Pascalis S; Occhiello L; Fraia AD; Messina V; Sangiovanni V; Claar E; Coppola N;
    Int J Antimicrob Agents; 2020 Sep; 56(3):106067. PubMed ID: 32599227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.
    Abdelaty LN; Elnaggar AA; Said AA; Hussein RRS
    Curr Drug Saf; 2020; 15(1):53-60. PubMed ID: 31573893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
    Taneja S; Duseja A; De A; Kumar V; Ramachandran R; Sharma A; Dhiman RK; Gupta KL; Chawla Y
    Nephrology (Carlton); 2018 Sep; 23(9):876-882. PubMed ID: 28703905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use of sofosbuvir-based regimens in the treatment of adolescents and children with chronic hepatitis C].
    He S; Wang XY; Han QY; Liu ZW
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jan; 29(1):83-86. PubMed ID: 33548971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting.
    Dhiman RK; Grover GS; Premkumar M; Taneja S; Duseja A; Arora S; Rathi S; Satsangi S; Roy A;
    J Hepatol; 2019 Dec; 71(6):1076-1085. PubMed ID: 31325468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group.
    Tsuji K; Kurosaki M; Itakura J; Mori N; Takaki S; Hasebe C; Akahane T; Joko K; Yagisawa H; Takezawa J; Nakata R; Kusakabe A; Kojima Y; Kimura H; Tamada T; Kobashi H; Mitsuda A; Kondou M; Ogawa C; Uchida Y; Sohda T; Narita R; Izumi N
    J Gastroenterol; 2018 Oct; 53(10):1142-1150. PubMed ID: 29626296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug-Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA).
    Fagiuoli S; Toniutto P; Coppola N; Ancona DD; Andretta M; Bartolini F; Ferrante F; Lupi A; Palcic S; Rizzi FV; Re D; Alvarez Nieto G; Hernandez C; Frigerio F; Perrone V; Degli Esposti L; Mangia A
    Ther Clin Risk Manag; 2023; 19():57-65. PubMed ID: 36699017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.